WO2009025759A8 - Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof - Google Patents

Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof Download PDF

Info

Publication number
WO2009025759A8
WO2009025759A8 PCT/US2008/009763 US2008009763W WO2009025759A8 WO 2009025759 A8 WO2009025759 A8 WO 2009025759A8 US 2008009763 W US2008009763 W US 2008009763W WO 2009025759 A8 WO2009025759 A8 WO 2009025759A8
Authority
WO
WIPO (PCT)
Prior art keywords
claudin
hcv
infection
entry
virus
Prior art date
Application number
PCT/US2008/009763
Other languages
French (fr)
Other versions
WO2009025759A1 (en
Inventor
Tatjana Dragic
Emmanuel Cormier
Claire Bertaux
Laurent Meertens
Original Assignee
Progenics Pharmaceuticals Neva
Einstein Coll Med
Tatjana Dragic
Emmanuel Cormier
Claire Bertaux
Laurent Meertens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals Neva, Einstein Coll Med, Tatjana Dragic, Emmanuel Cormier, Claire Bertaux, Laurent Meertens filed Critical Progenics Pharmaceuticals Neva
Publication of WO2009025759A1 publication Critical patent/WO2009025759A1/en
Publication of WO2009025759A8 publication Critical patent/WO2009025759A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The tight junction proteins claudin 9 and claudin 6 are newly identified as being involved in HCV entry and infection of susceptible cells. The claudin 6 and claudin 9 proteins share a high degree of amino acid sequence identity, particularly in the first extracellular loop (ECLl) region of the proteins. Claudin 9 is shown to play a role in the entry of HCV of different genotypes, e.g., different Ia and Ib genotypes, in cells expressing the claudin 9 protein. The claudin 9 and claudin 6 proteins enhance virus infection of cells and afford new targets for generating protein and non-protein virus entry inhibitors, e.g., HCV entry inhibitors, to provide therapeutic intervention for combating virus infection, particularly, infection by different HCV of different genotypes.
PCT/US2008/009763 2007-08-17 2008-08-15 Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof WO2009025759A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96517607P 2007-08-17 2007-08-17
US60/965,176 2007-08-17

Publications (2)

Publication Number Publication Date
WO2009025759A1 WO2009025759A1 (en) 2009-02-26
WO2009025759A8 true WO2009025759A8 (en) 2009-07-30

Family

ID=40378445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009763 WO2009025759A1 (en) 2007-08-17 2008-08-15 Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof

Country Status (1)

Country Link
WO (1) WO2009025759A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221375A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
NZ594480A (en) 2009-02-20 2013-11-29 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
NO2499161T3 (en) 2009-11-11 2018-02-03
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
AU2012258087B2 (en) 2011-05-13 2017-07-20 Astellas Pharma Inc. Antibodies for treatment of cancer expressing claudin 6
KR102089477B1 (en) 2012-08-31 2020-03-17 더 가버너스 오브 더 유니버시티 오브 알버타 Methods for producing cells having a phenotype of a primary human hepatocytes and compositions
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
EP3247362A4 (en) 2014-11-17 2018-10-10 Context Biopharma Inc. Onapristone extended-release compositions and methods
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
CN113661175A (en) 2019-02-15 2021-11-16 整体分子公司 Antibodies comprising a common light chain and uses thereof
WO2020168059A1 (en) * 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2009025759A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
WO2009025759A8 (en) Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
EA202191537A1 (en) COMPOSITIONS AND METHODS FOR INHIBITION OF HEPATITIS B VIRUS GENE EXPRESSION
WO2008106507A3 (en) Mdm2/mdmx inhibitor peptide
MX2010008749A (en) Hepatitis c virus inhibitors.
ATE543873T1 (en) PRODUCTION OF 3-HYDROXYPROPIONIC ACID USING BETA-ALANINE PYRUVATE AMINOTRANSFERASE
WO2008069917A3 (en) Novel cyclic peptides
WO2007008657A3 (en) Hepatitis c virus inhibitors
WO2010081082A3 (en) Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
EA200900297A1 (en) HEPATITIS C VIRUS INHIBITORS
RU2016146198A (en) THERAPEUTIC DLL4-BINDING PROTEINS
EA200901241A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
MY152971A (en) Hepatitis c virus inhibitors
MX2011008045A (en) Hepatitis c virus inhibitors.
EA200900298A1 (en) HEPATITIS C VIRUS INHIBITORS
EA200870264A1 (en) ANTIBODY COMPOSITION
MX337936B (en) Hepatitis c virus inhibitors.
MX2009010492A (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells.
MX2010002557A (en) Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof.
BR112013028679A2 (en) hepatitis c virus inhibitors
WO2009038026A1 (en) Ctl inducer composition
ATE445406T1 (en) USE OF IRON(III) COMPLEX COMPOUNDS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795356

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 08795356

Country of ref document: EP

Kind code of ref document: A1